uploads///Wellbutrin

Valeant Pharmaceuticals’ U.S. Diversified Top Products after 4Q17

By

Updated

Wellbutrin: Revenue trends

In 4Q17, Valeant Pharmaceuticals International’s (VRX) Wellbutrin generated revenues of $67 million, a 10% growth on a quarter-over-quarter basis. In 4Q17, Wellbutrin’s YoY (year-over-year) growth was flat.

Wellbutrin is used for the treatment of major depressive disorder. In fiscal 2017, Wellbutrin had net revenues of $235 million. In the marketplace, Wellbutrin’s peers include Pfizer’s (PFE) Effexor, Novartis’s (NVS) Ritalin, and Allergan’s (AGN) Viibryd.

Article continues below advertisement

Isuprel and Xenazine: Revenue trends

In 4Q17, Isuprel generated revenues of $11 million compared to $42 million in 4Q16, a 74% YoY decline and a 52% decline quarter-over-quarter. In 2017, Isuprel generated revenues of $105 million.

Isuprel is used for the treatment of certain types of abnormal heartbeats, shock, and heart failure.

In 4Q17, Xenazine generated revenues of $24 million compared to $33 million in 4Q16, a 27% decline on a YoY basis and a 14% decline quarter-over-quarter. In 2017, Xenazine generated revenues of $113 million.

Xenazine is used for the treatment of chorea-associated Huntington’s disease.

Syprine and Cuprimine: Revenue trends

In 4Q17, Syprine reported revenues of $26 million, a 30% YoY growth and a 44% quarter-over-quarter growth. In 2017, Syprine generated net revenues of $91 million.

In 4Q17, Cuprimine reported revenues of $18 million, an 18% YoY decline and a 10% decline quarter-over-quarter. In 2017, Cuprimine reported revenues of $78 million.

Cuprimine is used for the treatment of individuals with Wilson’s disease.

Ativan and Migranal AG: Revenue trends

In 4Q17, Ativan and Migranal AG generated revenues of $15 million and $12 million, respectively, compared to $7 million and $14 million, respectively, in 4Q16. In 2017, Ativan reported revenues of $61 million.

In 4Q17, Migranal generated revenues of $12 million, a 14% decline on a YoY basis and a 14% decline on a quarter-over-quarter basis. In 2017, Migranal AG reported revenues of $53 million.

In the migraine drugs market, Migranal competes with GlaxoSmithKline’s (GSK) Imitrex and Pfizer’s (PFE) Relpax.

Advertisement

More From Market Realist